Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone

Journal of Dermatological Treatment

Volumn 18, Issue 4, 2007, Pages 243-245

  Scheinfeld, Noah ^a  

^a St Luke's Roosevelt ^*  (United States)

Author keywords

Anemia; Mycophenolate mofetil; Pemphigus vulgaris; Prednisone; Red blood cell

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOSPORIN; FOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ANAMNESIS; ANEMIA; APLASIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROCYTE; ERYTHROCYTE COUNT; FEMALE; HUMAN; LEUKOCYTE COUNT; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; TRANSPLANTATION;

ANEMIA; DRUG THERAPY, COMBINATION; ERYTHROCYTE COUNT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYCOPHENOLIC ACID; PEMPHIGUS; PREDNISONE;

EID: 34547629933     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701287324     Document Type: Article

References (9)

1. Pan TD, McDonald CJ. Cytotoxic agents. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia: WB Saunders; 2001. p. 180-204.
2. Orphan drug status granted for pemphigus vulgaris treatment. URL: http://www.factsandcomparisons.com/News/ArticlePage.aspx?cat=update&id=7244 (accessed December 5, 2006).
3. Treating pemphigus and pemphigoid immunosuppressants. URL: http://www.pemphigus.org/immunosuppressants.html (accessed December 5, 2006).
4. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142:1447-54.
5. Medline Plus. Mycophenolate mofetil. What side effects can this medication cause. URL: http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/ a601081.html (accessed January 24, 2007).
6. Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess. 2006;10:1-178.
7. Engelen W, Verpooten GA, Van der Planken M, Helbert MF, Bosmans JL, De Broe ME. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol. 2003;60:119-24.
8. Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol. 2004;15:1347-52.
9. Arbeiter K, Greenbaum L, Balzar E, Muller T, Hofmeister F, Bidmon B, et al. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol. 2000;14:195-7.